Potential Alzheimer’s Breakthrough Excites Researchers

There’s a potentially very exciting story in today’s New York Times that’s worth a look. Researchers doing mouse studies have…

Do you know what COPD stands for?

If not, don’t worry: you are not alone. However, considering that more than 13 million Americans suffer from the disease…

Prescribing Authority of Doctors Undermined

I was just getting my daily dose of pharma news from Pharmalot and ran across an interesting blog post about…

More Than 50 Medicines in Development for COPD, Third Leading Cause of Death in U.S.

Washington, D.C. (February 2, 2012) — America’s biopharmaceutical research companies are working on 54 medicines to treat chronic obstructive pulmonary…

A Patient View of a Phase I Immunotherapy Clinical Trial

I want to recommend an interesting piece in Salon. Author Mary Elizabeth Williams writes about her participation in a Phase…

PhRMA Statement Regarding Prescription Drug User Fee Act Reauthorization

Washington, D.C. (February 1, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President for Scientific and Regulatory…

James M. ("Mit") Spears Named Executive Vice President & General Counsel

Washington, D.C. (January 31, 2012) — The Pharmaceutical Research and Manufacturers of America (PhRMA) announced today that Mit Spears will…

New Cooperation in the Fight Against Neglected Tropical Disease

Impressive efforts are increasingly underway to bring together biopharmaceutical research companies, world governments and key non-governmental organizations (NGOs) in the…

Working Together, We Build on the Past

Earlier this month, I wrote about the news that India has gone a full year without a new polio diagnosis…

Continued Support for the Future of Benefit-Risk Assessment

Today, PhRMA announced that we are transferring the future development of our benefit-risk assessment framework to the Centre for Innovation…

PhRMA Transitions Management of Benefit-Risk Action Team Framework to CIRS

CIRS To Integrate BRAT Work Into New Science-Based UMBRA Initiative Washington, D.C. and London, U.K. (January 30, 2012) — The…

Viewing DTC Ads Fairly

Yesterday, the New York Times’ Well blog posted a commentary on DTC advertising. Although its underlying tone was one of…

Giving Back

I think it’s great that billionaire David Rubenstein has decided to donate half the $15 million needed to repair the…

A More Complete Picture on the Issue of Access to Cancer Medicines

In his recent commentary, Merill Goozner of the Fiscal Times looks at the affordability of cancer medicines. Goozner rightly points…

The (bad) business model of counterfeit medicine

As I’ve mentioned before, mixed methodologies is an instant triple shot of espresso for me – I love the way…

Will an inspirational SOTU lead to action?

President Obama's State of the Union address and its focus on jobs comes at a time when America's biopharmaceutical research…

PhRMA Statement on State of the Union

Washington, D.C. (January 24, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani released…

Joining the SOTU Conversation

Like millions of other Americans, I'll be watching the president and Governor Daniels offer their ideas for helping to address…

Improving the lives of patients

A recent editorial in the Cherokee Chronicle Times highlights the importance of new medicines for patients. Innovative prescription medicines and…

Peeling Away the Layers of Research

Over the weekend, I watched a documentary called Objectified, about industrial design and the people who work in the field.…